Rheumatoid Arthritis

It is almost four years since EULAR published its definition of difficult-to-treat (D2T) rheumatoid arthritis (RA) (1). This marked a formal recognition of the group of patients who, despite the…

The development of JAK inhibitors represents an advance for the treatment of inflammatory rheumatic diseases. However, the enthusiasm in using this target has waned since the publication of the ORAL…

Pregnancy in lupus patients is a complex situation, posing significant concerns for both patients and physicians due to the risk of adverse pregnancy outcomes. These outcomes can range from increased…

Multi-modal analysis of rheumatoid arthritis (RA) synovitis pathotypes enables more accurate choices of first line cDMARDs treatment, suggesting a predictive value to synovial biopsy. The…

Cardiovascular comorbidities represent a significant cause of morbidity and mortality in patients with rheumatoid arthritis, who are up to twice as likely to develop coronary artery disease compared…

Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the…

Dual seropositivity (rheumatoid factor (RF) and/or anti-citrullinated protein antibodies (ACPA) as well as shared epitope (SE) are known to be associated with poor prognosis and structural damage in…

Wednesday was Day One at EULAR 2024 in Vienna. While the day was a slow start, the poster halls and auditoriums quickly filled with thousands of rheumatologists, eager to reunite at this…

While everyone is getting ready for EULAR 2024, dissecting the scientific program for what promises to be an exciting knowledge exchange, I am personally very enthusiastic about potential new drugs…

On the first day of EULAR 2024, I am debating Janet Pope. To make it more challenging, it’s about JAK inhibitor safety, and I have been allocated to argue against the regulatory safety warning…